Table 3

Time to herpes zoster event according to the Cox proportional hazard model

ModelCharacteristicsBSEHRCI (95%)p Value
Model 1Age0.010.0061.011.00 to 1.020.048
Sex—female0.250.1561.290.95 to 1.750.11
Charlson Comorbidity Index score0.040.0581.040.93 to 1.170.46
Steroid exposure0.080.0231.081.04 to 1.13<0.001
Treatment previous to 2002 with c-DMARDs−0.060.1720.940.67 to 1.320.73
Group A-(no DMARDs)Ref.1.00
Group B-(c-DMARDs)0.100.1941.110.76 to 1.620.60
Group C-(anti-TNF-α)0.250.3181.280.69 to 2.40.43
Group D-(anti-TNF-α + c-DMARDs)0.860.2962.371.32 to 4.220.004
Model 2Age0.010.0061.011.01 to 1.020.049
Sex—female0.250.1561.290.95 to 1.750.10
Charlson Comorbidity Index score0.040.0581.040.93 to 1.170.47
Steroid exposure0.080.0231.081.04 to 1.13<0.001
Treatment previous to 2002 with c-DMARDs−0.060.1720.940.67 to 1.320.71
Group A-(no DMARDs)Ref.1.00
Group B-(c-DMARDs)0.100.1941.110.76 to 1.620.59
Group E-(MAB-anti-TNF-α)0.160.4241.180.51 to 2.700.70
Group F-(MAB-anti-TNF-α + c-DMARDs)0.620.3561.860.93 to 3.750.08
Group G-(etanercept)0.340.3961.410.65 to 3.060.39
Group H-(etanercept + c-DMARDs)1.280.3913.601.67 to 7.750.001
  • *Steroid exposure was defined as the number of prescriptions of steroid-containing preparations filled at the pharmacy during treatment period.

  • DMARD, disease-modifying anti-rheumatic drug.